Use of embolic protection devices during saphenous vein graft (SVG) interventions is associated with an increase in procedural complications without corresponding improvements in clinical outcomes for ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

PARIS, France—A new analysis of more than 10,000 patients likely slams the door on routinely using cerebral embolic protection for stroke prevention in patients with aortic stenosis undergoing TAVI.

SANTA CRUZ, Calif., Oct. 23, 2025 /PRNewswire/ -- Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient ...

Emboline’s new financing could help jumpstart the company into a clinical trial and launch of its embolic protection device used in connection with Transcatheter Aortic Valve Replacement. The Santa ...

WASHINGTON, DC — An embolic-protection device delivered percutaneously via the radial artery and used during transcatheter aortic-valve implantation (TAVI) in high-risk patients with aortic stenosis ...

WASHINGTON, DC — Are surrogate end points enough to recommend a treatment that seems safe but hasn't "worked" by clinical-trial standards, but many agree ought to work? A pair of catheter-delivered ...

A multicenter EPIC (FiberNet Embolic Protection System in Carotid Artery Stenting Trial) study found that the FiberNet Embolic Protection System had a 97.5 percent success rate when used in patients ...

Italian medtech company AorticLab has been banned from selling its embolic protection devices in Germany following a complaint from U.S.-based competitor Emboline. A Munich regional court is the ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...